A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Investigating an investigational medication combination for advanced urothelial carcinoma

Recruiting
18 years - 100 years
All
1 Location

Brief description of study.

The purpose of this study is to evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Urothelial Carcinoma
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

  • Diagnosis of urothelial carcinoma

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 19 Feb 2024. Study ID: 1902515462 (516-003)

This study investigates the effects of an investigational medication combination for patients with advanced or metastatic urothelial carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system, including the bladder and urethra.

Participants in the study will receive a combination of investigational medications. The study aims to assess how this combination works in treating the cancer.

  • Who can participate: Adults diagnosed with urothelial carcinoma may be eligible to participate. Participants must be within a specific age range. For detailed criteria, please refer to the official study listing.
  • Study details: Participants will receive a combination of investigational medications.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here